SCHEMBL649623

SCHEMBL649623

CCCCn1c(-c2ccccc2)nc(Cl)c1CNCc1ccc2c(c1)OCCO2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
LMNA P02545 2/20 0.46
KDM4E B2RXH2 3/20 0.39
GFER P55789 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TSHR P16473 1/20 0.39
CYP2D6 P10635 2/20 0.38
TDP1 Q9NUW8 1/20 0.37
ALDH1A1 P00352 5/20 0.37
KDM1A O60341 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
RAB9A P51151 1/20 0.36
PDCD1 Q15116 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
HPGD P15428 2/20 0.36
PDE4B Q07343 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL652376 0.86 C5AR1 (0.58) C5AR1SMN1; SMN2L3MBTL1LMNATSHR
SCHEMBL29154097 0.84 C5AR1 (0.66) C5AR1SMN1; SMN2L3MBTL1LMNAKDM4E
SCHEMBL649257 0.83 C5AR1 (0.56) C5AR1SMN1; SMN2L3MBTL1LMNAKDM4E
SCHEMBL1912840 0.83 C5AR1 (0.63) C5AR1SMN1; SMN2L3MBTL1LMNAKDM4E
SCHEMBL648416 0.83 C5AR1 (0.58) C5AR1SMN1; SMN2L3MBTL1LMNAKDM4E
SCHEMBL648614 0.83 C5AR1 (0.55) C5AR1SMN1; SMN2L3MBTL1LMNATSHR
SCHEMBL648693 0.83 C5AR1 (0.55) C5AR1SMN1; SMN2L3MBTL1LMNAMEN1
SCHEMBL1913081 0.81 C5AR1 (0.54) C5AR1SMN1; SMN2L3MBTL1LMNATSHR
SCHEMBL650515 0.81 C5AR1 (0.54) C5AR1SMN1; SMN2L3MBTL1LMNATSHR
SCHEMBL648139 0.81 C5AR1 (0.54) C5AR1SMN1; SMN2L3MBTL1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-20070208048-A1 New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2007-09-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490343-A1 NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS Neurogen Corporation (US) 2004-12-29 EP disclosed
US-20040116424-A1 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION 2004-06-17 US disclosed
WO-2003082829-A1 NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208048-A1 New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators C3AR1, C5AR1, C5AR2 C5AR1 2/4885SMN1; SMN2 4667/4885L3MBTL1 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.